Detalhe da pesquisa
1.
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Lancet Oncol
; 18(9): 1202-1210, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28729151